Company intelligence / Profile preview

Arontier

Seoul, Seoul, Republic of Koreaarontier.co ↗

Ownership: Private
Development stage: Preclinical

Overview

Arontier has several drug candidates in discovery phase, including SJA-22, SJA-71, and SJA-23 for solid tumors and breast cancer. The company presented research results on anti-CAF candidates and mechanism at AACR 2023.

Therapeutic areas: OncologyEndocrinologyNephrology
Modalities: Small molecule drugsAntibody drug conjugates (ADC)Degrader-antibody conjugates
Industry: Biotech

Drug pipeline

1 asset

ARC2-001

Pre-clinical

Indications: Cancer

Partnerships

Dongkook pharmaceuticalHLB bioStepSAMJIN PHARMKMEDI HubFUTURE MEDICINENEX-IYonsei University Health SystemKRICT

Beyond the preview

Go deeper on Arontier.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arontier.

Explore the full profile